You are receiving a personalized analytical report that goes beyond standard result interpretation. Your data has been processed by an advanced analytical system that performed a multi-level comparative analysis of complex biochemical patterns. What you see is not a simple opinion, but a data synthesis designed to identify subtle relationships and patterns that may be overlooked in traditional assessment. Treat this document as an advanced support tool providing deep insight into your pet's current biochemical state — taking into account its species, breed, age, and individual characteristics.
Alanine aminotransferase (ALT) is an enzyme primarily found in the liver cells of dogs, and it plays a crucial role in amino acid metabolism. It facilitates the conversion of alanine and alpha-ketoglutarate to pyruvate and glutamate, which are important for energy production and various metabolic pathways. ALT is released into the bloodstream when liver cells are damaged or destroyed, making it a sensitive marker for liver cell injury. According to the WSAVA Global Nutrition Guidelines, monitoring liver enzyme levels, including ALT, is essential for assessing liver health and function in dogs.
In this specific case, the ALT level of 285 U/L is significantly elevated compared to the laboratory-provided reference range of 10-100 U/L. This indicates a marked increase, suggesting liver cell damage or increased enzyme production. Given that the patient is a 7-year-old neutered male Labrador Retriever, this elevation is concerning, especially in the context of the reported symptoms of vomiting, reduced appetite, and lethargy. These clinical signs, combined with the elevated ALT, suggest a potential underlying hepatic issue that warrants further investigation.
Elevated ALT levels in dogs are commonly associated with various conditions, including hepatic inflammation (hepatitis), hepatic lipidosis, or exposure to hepatotoxic substances. In Labrador Retrievers, there is also a predisposition to conditions such as hypothyroidism, which can indirectly affect liver function. When ALT is elevated, it is important to evaluate other liver-related parameters such as alkaline phosphatase (ALP), bilirubin, and bile acids to gain a comprehensive understanding of liver health. Hypoalbuminaemia, as mentioned in the owner's comments, could indicate impaired liver synthetic function, further supporting the suspicion of hepatic dysfunction.
If the elevated ALT level remains unaddressed, the underlying liver condition may progress, potentially leading to chronic liver disease or liver failure. This could result in worsening clinical signs, including jaundice, ascites, and coagulopathy, over weeks to months. However, if the cause of the liver enzyme elevation is identified and appropriately managed, such as through dietary modifications, medication, or addressing any underlying conditions, the prognosis can be significantly improved. Early intervention can help stabilize liver function and improve the dog's quality of life, particularly in a breed like the Labrador Retriever, which is generally resilient with proper care.
Aspartate aminotransferase (AST) is an enzyme that plays a crucial role in amino acid metabolism, specifically in the transamination process where it facilitates the conversion of aspartate and alpha-ketoglutarate to oxaloacetate and glutamate. This enzyme is present in various tissues, including the liver, heart, skeletal muscle, and kidneys, but it is most abundant in the liver. In dogs, AST is released into the bloodstream when there is damage to these tissues, making it a useful marker for assessing tissue injury, particularly hepatic injury. According to the WSAVA guidelines, AST is often evaluated alongside other liver enzymes such as ALT and ALP to provide a comprehensive picture of liver health and function.
In this specific case, the AST level of 87 U/L is elevated compared to the laboratory-provided reference range of 15-55 U/L. This indicates an increase of 32 U/L above the upper limit of normal, suggesting potential tissue damage. Given the breed, age, and neuter status of this 7-year-old male Labrador Retriever, this elevation could be significant. Labrador Retrievers are predisposed to certain conditions such as hypothyroidism and obesity-related dyslipidaemia, which can indirectly affect liver function. The elevated AST, combined with the owner's observations of vomiting, reduced appetite, and lethargy, raises concerns about possible hepatic or muscular issues.
Elevated AST levels in dogs can be associated with a variety of conditions, including liver disease, muscle injury, or even cardiac issues. In the context of liver disease, AST is often elevated alongside ALT, which is more liver-specific. If ALT is also elevated, this would strengthen the suspicion of hepatic dysfunction. In Labrador Retrievers, conditions such as hypothyroidism can lead to secondary liver enzyme elevations due to altered metabolism. Additionally, muscle injury or strenuous exercise can also cause AST elevations, though this is less likely given the clinical signs reported. It is important to evaluate other parameters such as ALT, ALP, and bilirubin to better understand the underlying cause of the AST elevation.
If the elevated AST remains unaddressed, and if it is indeed indicative of liver disease, the patient may experience progressive hepatic dysfunction. This could lead to more severe clinical signs such as jaundice, ascites, or hepatic encephalopathy over time. However, if the underlying cause is identified and managed appropriately, such as through dietary modifications, medication, or addressing any primary conditions like hypothyroidism, the prognosis can be significantly improved. Maintaining liver enzyme levels within the normal range is crucial for the long-term health and quality of life of a Labrador Retriever, as it helps ensure proper metabolic function and reduces the risk of chronic liver disease.
Alkaline phosphatase (ALP) is an enzyme found in various tissues throughout the body, with particularly high concentrations in the liver, bone, kidney, and intestine. In dogs, ALP plays a crucial role in the breakdown of proteins and is involved in processes such as bone mineralization and liver function. The enzyme is produced by the liver and bone cells, and its levels can be influenced by factors such as age, breed, and physiological state. According to the WSAVA Global Nutrition Guidelines, maintaining a balanced diet is essential for optimal liver function, which in turn can affect ALP levels. ALP is often measured as part of a comprehensive biochemical panel to assess liver health and other systemic conditions in dogs.
In this specific case, the ALP level of 520 U/L is significantly elevated compared to the laboratory-provided reference range of 20-150 U/L. This indicates that the ALP is approximately 3.5 times higher than the upper limit of normal for this laboratory's standards. Given that the patient is a 7-year-old neutered male Labrador Retriever, this elevation is noteworthy. Labradors are predisposed to certain conditions that can affect liver function, such as hypothyroidism and obesity-related dyslipidaemia, which could contribute to elevated ALP levels. The age and neuter status of the dog also play a role, as older and neutered dogs may have different baseline levels compared to younger, intact animals.
Elevated ALP levels in dogs can be associated with a variety of conditions, including liver disease, bone disorders, and endocrine disorders such as hyperadrenocorticism (Cushing's disease). In the context of the owner's report of vomiting, reduced appetite, and lethargy, these symptoms could suggest a hepatic or systemic issue. Other parameters that would typically be evaluated alongside ALP include alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin, which can provide additional insights into liver function. In Labradors, hypothyroidism could also be a differential consideration, as it can lead to secondary liver enzyme elevations.
If the underlying cause of the elevated ALP is not addressed, the dog may experience progressive liver dysfunction, leading to worsening clinical signs such as jaundice, weight loss, and further lethargy. Over time, untreated liver disease can result in irreversible damage and potentially life-threatening complications. Conversely, if the cause is identified and appropriately managed, such as through dietary modifications, medical therapy, or addressing any underlying endocrine disorders, the prognosis can be significantly improved. Early intervention can stabilize liver function and improve the dog's quality of life, potentially reversing some of the clinical signs and preventing further deterioration.
Gamma-glutamyl transferase (GGT) is an enzyme that plays a crucial role in the metabolism of glutathione and the transfer of amino acids across the cellular membrane. It is primarily produced in the liver, but also found in the kidney, pancreas, and intestine. In dogs, GGT is a marker of hepatobiliary function and is often used to assess liver health. According to the WSAVA Liver Disease Guidelines, GGT can be indicative of cholestasis or biliary obstruction when elevated, as it reflects the activity of the biliary epithelium. Its regulation is influenced by various factors, including liver function and the presence of certain medications or diseases that induce enzyme production.
In this specific case, the GGT level is 28 U/L, which is significantly above the provided reference range of 1-12 U/L. This elevation suggests an abnormality in the hepatobiliary system, particularly in a 7-year-old neutered male Labrador Retriever. Given the breed's predisposition to certain conditions such as hypothyroidism and obesity-related dyslipidaemia, this elevated GGT could be indicative of underlying hepatic stress or dysfunction. The fact that the value is more than double the upper limit of the reference range underscores the need for further investigation into potential liver-related issues.
Elevated GGT levels in dogs are commonly associated with liver diseases such as cholestasis, hepatic lipidosis, or biliary obstruction. In the context of this Labrador Retriever, other liver enzymes such as ALT and ALP should also be evaluated to provide a comprehensive picture of liver health. An increase in GGT, especially when accompanied by elevated ALT and ALP, may suggest cholestatic liver disease or hepatocellular damage. Additionally, hypoalbuminaemia, as noted in the owner's comments, could indicate impaired protein synthesis, further supporting the possibility of hepatic dysfunction. It is important to consider other parameters such as bilirubin and bile acids to assess the extent of liver involvement.
If the elevated GGT remains unaddressed, the dog may experience progressive liver damage, leading to further deterioration of hepatic function and potential complications such as hepatic encephalopathy or coagulopathy. Over time, this could result in significant clinical decline, affecting the dog's quality of life. However, if the underlying cause of the elevated GGT is identified and managed appropriately, the prognosis can be significantly improved. Treatment may involve addressing any underlying conditions, dietary modifications, and potentially the use of hepatoprotective agents. Maintaining GGT within the normal range is crucial for the long-term health and well-being of this Labrador Retriever, as it indicates stable liver function and reduced risk of hepatic complications.
Bilirubin is a yellow compound that is a byproduct of the normal breakdown of red blood cells. It is processed by the liver, where it is conjugated and then excreted in bile. In dogs, bilirubin plays a crucial role in assessing liver function and the body's ability to process and eliminate waste products. The WSAVA guidelines emphasize the importance of bilirubin as a marker for hepatic function, as elevated levels can indicate liver dysfunction or hemolysis. The liver's ability to conjugate and excrete bilirubin is essential for maintaining normal physiological processes and preventing jaundice.
In this specific case, the bilirubin level is 0.6 mg/dL, which is slightly above the laboratory's reference range of 0.1-0.5 mg/dL. For a 7-year-old neutered male Labrador Retriever, this elevation, although mild, is noteworthy. It suggests a potential issue with bilirubin metabolism or excretion, possibly indicating early liver dysfunction or increased red blood cell breakdown. Given the breed's predisposition to certain conditions, such as hypothyroidism, which can affect liver function, this finding warrants further investigation.
Elevated bilirubin levels in dogs can be associated with several conditions, including liver disease, bile duct obstruction, or hemolytic anemia. In the context of this Labrador Retriever, the mild elevation could be an early sign of hepatic dysfunction, especially when considered alongside the owner's report of vomiting, reduced appetite, and lethargy. These clinical signs, combined with the bilirubin result, suggest that other liver parameters such as ALT, ALP, and bile acids should be evaluated to gain a comprehensive understanding of the liver's health. In Labradors, hypothyroidism can also contribute to altered liver enzyme levels, so thyroid function tests might be indicated.
If this bilirubin elevation remains unaddressed, the underlying cause, whether hepatic or hematologic, could progress, leading to more significant liver damage or systemic effects. Over time, this could result in jaundice, further gastrointestinal disturbances, and potentially more severe systemic illness. However, if the cause is identified and managed appropriately, such as through dietary adjustments, medication, or addressing any underlying thyroid issues, the prognosis can be favorable. Maintaining bilirubin within the normal range is crucial for the long-term health of this Labrador Retriever, as it indicates effective liver function and overall metabolic health.
Albumin is a critical plasma protein synthesized primarily by the liver, playing a vital role in maintaining oncotic pressure and serving as a carrier for various substances, including hormones, vitamins, and drugs. In dogs, albumin is essential for fluid balance and transport functions, and its production is tightly regulated by the liver in response to nutritional status and systemic demands. According to the WSAVA Global Nutrition Guidelines, maintaining adequate protein intake is crucial for optimal albumin synthesis, particularly in breeds like the Labrador Retriever, which may have specific nutritional requirements.
In this 7-year-old neutered male Labrador Retriever, the albumin level is 2.1 g/dL, which is below the laboratory's reference range of 2.5-3.5 g/dL. This indicates hypoalbuminaemia, a condition where albumin levels are lower than normal. The deviation from the reference range is significant, as the value is 0.4 g/dL below the lower limit. This finding is consistent with the owner's observations of vomiting, reduced appetite, and lethargy, which may suggest an underlying hepatic dysfunction or other systemic issues affecting protein synthesis or loss.
Hypoalbuminaemia in dogs can result from several conditions, including liver disease, protein-losing enteropathy, protein-losing nephropathy, or malnutrition. In the context of this Labrador Retriever, the combination of hypoalbuminaemia with symptoms such as vomiting and lethargy raises the suspicion of hepatic dysfunction, possibly due to chronic liver disease or inflammation. Other laboratory parameters that might be affected include elevated liver enzymes (ALT, ALP) and bile acids, which would support a diagnosis of liver dysfunction. Additionally, hypoalbuminaemia may lead to fluid imbalances, potentially causing ascites or edema if severe.
If the hypoalbuminaemia remains unaddressed, the dog may experience progressive clinical deterioration, including worsening lethargy, potential development of ascites, and further decline in nutritional status. Over time, this could lead to significant morbidity and impact the dog's quality of life. However, if the underlying cause is identified and appropriately managed, such as through dietary modifications, medical treatment of liver disease, or addressing any protein-losing conditions, the prognosis can improve significantly. Early intervention can stabilize albumin levels, improve clinical symptoms, and enhance the overall health and longevity of the dog.
Total protein plays a crucial role in maintaining the oncotic pressure of blood, transporting nutrients, and supporting immune function in dogs. It is composed of various proteins, including albumin and globulins, which are essential for various physiological processes, including healing and response to infection. A balanced total protein level is vital for overall health, as it reflects the dog's nutritional status and liver function, among other factors.
Bile acids are crucial components in the digestive process of dogs, serving primarily to facilitate the emulsification and absorption of dietary fats in the small intestine. They are synthesized in the liver from cholesterol and stored in the gallbladder, being released into the intestine in response to food intake. The enterohepatic circulation allows for the reabsorption of bile acids back into the liver, where they can be reused. This cycle is tightly regulated, and any disruption can indicate hepatic dysfunction or biliary obstruction. According to the WSAVA Liver Disease Guidelines, elevated bile acids are a sensitive marker for liver dysfunction, as they reflect the liver's ability to reabsorb and process these compounds efficiently. In this context, bile acids serve as a functional test of hepatic integrity and portal circulation efficiency.
In this specific case, the bile acids level of 45 µmol/L is significantly elevated above the laboratory reference range of 0-15 µmol/L. This indicates a marked increase, suggesting impaired hepatic function or possible cholestasis in this 7-year-old neutered male Labrador Retriever. Given the breed's predisposition to conditions like hypothyroidism and obesity-related dyslipidaemia, which can indirectly affect liver function, this result is particularly concerning. The elevation is three times the upper limit of the normal range, which is clinically significant and warrants further investigation to determine the underlying cause of this hepatic dysfunction.
Elevated bile acids in dogs can be associated with various hepatic conditions, including hepatocellular damage, cholestasis, or portosystemic shunts. In Labradors, it is essential to consider the potential for concurrent hypothyroidism, which can exacerbate liver enzyme abnormalities. Other parameters that might be affected include ALT and ALP, which are often elevated in liver disease, and hypoalbuminaemia, indicating impaired protein synthesis. The combination of elevated bile acids with increased ALT and ALP would strongly suggest true hepatic dysfunction rather than mere enzyme induction. It is crucial to assess these parameters in conjunction with clinical signs such as vomiting, anorexia, and lethargy, which are consistent with liver disease.
If this abnormality remains unaddressed, the clinical trajectory for this patient could involve progressive hepatic insufficiency, leading to further systemic complications such as coagulopathy, hepatic encephalopathy, or ascites over weeks to months. The prognosis would depend on the underlying cause; for instance, a portosystemic shunt might be surgically correctable, whereas chronic hepatitis could require long-term medical management. Early identification and management of the underlying cause can significantly improve the prognosis, potentially stabilizing liver function and alleviating clinical signs. For a Labrador Retriever of this age, maintaining liver health is crucial for longevity and quality of life, and addressing this elevation promptly could prevent further hepatic deterioration and associated complications.
Glucose plays a crucial role in a dog's metabolism, serving as the primary energy source for cells and vital for maintaining normal physiological functions. It is essential for proper brain function and overall energy levels, influencing a dog's activity and well-being. The body regulates glucose levels through various hormones, primarily insulin, ensuring that energy demands are met efficiently throughout the day.
BUN, or blood urea nitrogen, is a crucial parameter that reflects the dog's protein metabolism and kidney function. It is produced in the liver from ammonia, a byproduct of protein breakdown, and is then excreted by the kidneys. Monitoring BUN levels helps assess how well the kidneys are filtering waste products from the blood, which is vital for maintaining overall health in dogs, especially as they age and may develop various health conditions.
Creatinine is a waste product formed from the normal breakdown of muscle tissue and is primarily eliminated from the body by the kidneys. In dogs, the measurement of creatinine levels is crucial for assessing kidney function, as elevated levels can indicate impaired renal clearance and potential kidney disease. Maintaining appropriate creatinine levels is essential for overall health, as it reflects the kidneys' ability to filter and excrete waste products effectively.
White blood cells (WBC) play a crucial role in a dog's immune system, helping to defend against infections and diseases. They are essential for identifying and responding to pathogens, and their levels can indicate the body's response to various health challenges. In dogs, the WBC count can fluctuate based on numerous factors, including stress, infection, and inflammation, reflecting the overall health status of the animal.
Red blood cells (RBCs) are crucial components of the blood, responsible for transporting oxygen from the lungs to tissues throughout the body and returning carbon dioxide to the lungs for exhalation. In dogs, RBCs are produced in the bone marrow under the regulation of erythropoietin, a hormone primarily produced by the kidneys. The lifespan of canine RBCs is approximately 100-120 days, after which they are removed from circulation by the spleen. Maintaining an adequate RBC count is essential for ensuring sufficient oxygen delivery to meet the metabolic demands of the body's tissues. According to the WSAVA Global Nutrition Guidelines, proper nutrition supports hematopoiesis, the process of forming new blood cells, including RBCs.
In this specific case, the RBC count for the Labrador Retriever is 5.2 million cells per microliter, which is below the laboratory-provided reference range of 5.5 to 8.5 million cells per microliter. This indicates a mild decrease in RBC count, suggesting a condition known as anemia. Given the breed, age, and neuter status of this 7-year-old male Labrador Retriever, this finding warrants further investigation to determine the underlying cause. Anemia in dogs can result from various factors, including nutritional deficiencies, chronic diseases, or acute blood loss.
Clinically, a decreased RBC count can be associated with conditions such as chronic kidney disease, where erythropoietin production is impaired, or with chronic inflammatory diseases that affect the bone marrow's ability to produce RBCs. In Labradors, hypothyroidism is a common condition that can lead to mild anemia due to reduced metabolic rate and bone marrow activity. Other parameters that might be affected include hemoglobin and hematocrit, which would also likely be decreased if anemia is present. It is important to evaluate these alongside RBC count to gain a comprehensive understanding of the dog's hematological status.
If this mild anemia remains unaddressed, the dog may experience progressive lethargy, reduced exercise tolerance, and potentially more severe clinical signs as the body's tissues receive insufficient oxygen. Over time, this could lead to compensatory mechanisms such as increased heart rate and cardiac output, which may strain the cardiovascular system. However, if the underlying cause of the anemia is identified and appropriately managed, such as through dietary adjustments or treatment of an underlying disease, the RBC count can return to normal, improving the dog's energy levels and overall health. Maintaining RBC count within the normal range is crucial for the long-term health and vitality of a Labrador Retriever, ensuring adequate oxygenation of tissues and optimal physiological function.
Hemoglobin (HGB) plays a crucial role in a dog's physiology by transporting oxygen from the lungs to the tissues and facilitating the return of carbon dioxide to the lungs for exhalation. It is an essential component of red blood cells, and its levels can provide insights into a dog's overall health, particularly in relation to anemia or other blood disorders. Maintaining appropriate hemoglobin levels is vital for ensuring that the body's organs and systems receive adequate oxygen to function optimally.
Copper-associated chronic hepatitis
Labrador Retrievers are genetically predisposed to copper accumulation that causes progressive hepatocellular damage. The pronounced ALT 285 U/L, elevated bile acids 45 µmol/L and hypoalbuminaemia 2.1 g/dL fit the pattern of chronic hepatocellular disease leading to synthetic failure.
Extrahepatic or intrahepatic cholestasis (e.g. gallbladder mucocele, biliary obstruction)
Marked ALP 520 U/L and GGT 28 U/L with mild hyperbilirubinaemia 0.6 mg/dL suggest cholestatic involvement. Vomiting and inappetence are common clinical signs of biliary obstruction in dogs.
Hyperadrenocorticism (steroid-induced hepatopathy)
Marked ALP elevation in a middle-aged dog with mild ALT and AST increases can be driven by cortisol excess. However, bile acids are often normal in HAC, making this less compelling but still possible.
Primary hepatic neoplasia or metastatic disease
Neoplastic infiltration can elevate ALT, ALP, GGT and bile acids while reducing albumin, and can cause vomiting. Absence of marked anaemia or cachexia makes it less likely but still a consideration.
Pancreatitis with secondary reactive hepatopathy
Vomiting and lethargy are classic for pancreatitis, which may cause secondary hepatocellular enzyme elevation. The degree of bile acid rise and hypoalbuminaemia is more suggestive of primary hepatic disease, so this is lower on the list.
| 🟡 | Blood | Requires monitoring | RBC |
| 🔴 | Liver | Requires veterinary consultation | ALT, AST, ALP, GGT, Bilirubin, Albumin, Bile Acids |
| 🟢 | Kidneys | Within normal range | |
| 🟢 | Metabolism | Within normal range | |
| 🟢 | Immune System | Within normal range |
Prompt veterinary attention advised. The simultaneous presence of ALT 285 U/L (almost three times the upper limit), ALP 520 U/L (more than three times high-normal), GGT 28 U/L, bile acids 45 µmol/L and hypoalbuminaemia 2.1 g/dL points toward primary hepatopathy with developing synthetic compromise. According to the WSAVA Liver Disease Guidelines 2022, dogs with elevated bile acids and low albumin should undergo imaging and potentially biopsy without delay to identify treatable causes before irreversible fibrosis sets in.
In response to your question: The pattern of markedly elevated ALT 285 U/L, ALP 520 U/L, GGT 28 U/L and bile acids 45 µmol/L alongside low albumin 2.1 g/dL is highly suggestive of clinically significant hepatobiliary disease rather than mere enzyme induction. These changes mean hepatocytes are being damaged (ALT, AST), bile is not flowing normally (ALP, GGT, bilirubin) and the liver’s ability to make proteins is compromised (albumin). While laboratory data alone cannot confirm a specific diagnosis, they do support the concern for true hepatopathy that merits prompt work-up.
As a 7-year-old Labrador Retriever, this patient sits in the breed and age window where copper-associated chronic hepatitis is well documented. Chronic copper accumulation leads to inflammation, hepatocellular necrosis, cholestasis and eventual fibrosis. The WSAVA Liver Standardization Guidelines recommend screening Labradors with unexplained ALT elevations for hepatic copper via liver biopsy.
Hypoalbuminaemia raises concern for diminished hepatic synthetic capacity or protein-losing processes. In the absence of azotaemia and with normal total protein 5.8 g/dL, loss through the kidneys or gut is less likely, pointing back to the liver. Mild hyperbilirubinaemia 0.6 mg/dL indicates early cholestasis, concordant with high ALP and GGT. Chronic hepatitis, biliary obstruction or steroid hepatopathy can all produce this pattern, but the combination of bile acids 45 µmol/L and low albumin tips the scale toward a primary hepatocellular disorder.
The mild RBC count decrease (5.2 × 10⁶/µL) may reflect anaemia of chronic disease or reduced hepatic production of iron-binding proteins. Progressive hepatic disease in Labradors can advance silently until 70–80 % of function is lost, making these laboratory warning signs particularly important.
Your dog’s liver is likely inflamed or under strain, which can explain why he feels nauseated, vomits intermittently and has less enthusiasm for meals. When liver cells are damaged, they release enzymes such as ALT into the bloodstream, and bile does not flow normally, leading to the build-up of substances that worsen appetite and cause lethargy. Low albumin means the liver is not keeping up with its job of producing essential proteins; this can make your dog tire easily and predispose him to fluid accumulation if the process continues. Although he appears to drink and urinate normally and his kidneys are working well, the liver findings indicate he is uncomfortable and his metabolism is not running smoothly. Early intervention now can help prevent progression to jaundice, abdominal distension or more pronounced weakness.
No medications or supplements were reported, so the clinical picture reflects the natural course of the disease process. The combination of vomiting and elevated bile acids indicates that food intake has probably been irregular, which can further stress the liver by causing fluctuating bile flow and promoting cholestasis. Decreased caloric intake also contributes to muscle catabolism, potentially exaggerating the hypoalbuminaemia. If over-the-counter anti-inflammatory drugs have been given for discomfort in the past (common in large breed dogs), they could exacerbate hepatic injury; highlight any such use to your veterinarian. The fact that glucose is normal suggests the liver is still maintaining blood sugar, but prolonged hyporexia risks dropping glycogen stores, especially in a large active breed.
Imagine two scenarios. In the first, no changes are made: vomiting persists, your dog’s caloric intake stays low, and hepatic inflammation progresses. Over the next month you might notice yellow discolouration of the eyes (jaundice), increased abdominal girth from fluid build-up and further lethargy. In the second scenario, diagnostics are pursued within the week, a liver-supportive diet is started immediately, and (if indicated) chelation or anti-inflammatory therapy begins. Within two to four weeks vomiting decreases, appetite improves and re-check bloodwork shows enzymes trending toward normal. By three months, albumin may return to normal and your dog resumes normal play sessions. The divergence of these paths underscores the leverage early intervention offers for liver disease in Labradors.
Begin structured, low-impact exercise such as two 20-minute leash walks daily to stimulate bile flow without exhausting your dog; excessive rest can worsen cholestasis. Provide a calm feeding environment to reduce stress-related cortisol surges that could amplify ALP elevation. Transition over five days to a veterinary hepatic diet formulated with highly digestible proteins and restricted copper to ease metabolic load; this directly supports the low albumin and high ALT findings. Maintain strict body weight monitoring: weigh every week aiming to keep weight stable at 32 kg because rapid weight loss can precipitate hepatic lipidosis. Lastly, ensure fresh water is always available and avoid table scraps high in fat, which can trigger vomiting and secondary pancreatitis that would compound liver stress.
An option your veterinarian might discuss is S-adenosyl-l-methionine (SAMe) at 18–20 mg/kg once daily (approx. 600 mg for a 32 kg dog). SAMe raises hepatic glutathione stores, aiding detoxification and potentially lowering ALT. Another common supplement is silybin-rich milk thistle extract at 5–10 mg/kg once daily; it exhibits antioxidant and antifibrotic effects beneficial in chronic hepatitis. Vitamin E at 10 IU/kg daily can scavenge free radicals generated during inflammation. If copper-associated hepatitis is confirmed, oral zinc acetate (5–7 mg elemental zinc/kg divided BID) may reduce intestinal copper absorption. Discuss each with your veterinarian because dosing may change after diagnostic clarification and drug interactions (e.g. with chelators like d-penicillamine) must be managed.
PHASE 1 — DIAGNOSTIC / STABILISATION (Days 1–14): Feed a commercial hepatic support canned diet (eg. Hill’s l/d or Royal Canin Hepatic) divided into four small meals of roughly 225 g each per day (total ~900 g wet weight, providing ~1,200 kcal for a 32 kg Labrador at rest). These diets supply highly digestible soy and egg proteins that minimise ammonia production and are low in copper (<1.5 mg/kg). Avoid high-fat table foods and treats; instead use pieces of the same diet baked into small chewy treats. This frequent-small-meal strategy smooths bile acid cycling, easing cholestasis.
PHASE 2 — TREATMENT SUPPORT (Weeks 3–8 or until re-test confirms improvement): Continue the hepatic diet but reduce meal frequency to three meals if vomiting subsides. If chelation therapy (d-penicillamine) is initiated, administer the drug on an empty stomach one hour before breakfast; give zinc or mineral supplements at least two hours after penicillamine to prevent interference. Incorporate 15 g steamed white fish or egg white to each meal for extra high-quality protein if albumin remains low. Add SAMe and silybin capsules with the evening meal to improve absorption with food fat.
PHASE 3 — LONG-TERM MAINTENANCE (After normalisation of key parameters): Transition over two weeks to a balanced home-cooked plan if desired: 45 % boiled skinless turkey, 30 % cooked white rice, 15 % steamed carrots/zucchini, 10 % scrambled egg white, supplemented with a canine multivitamin free of added copper. Feed two meals totaling ~1,400 kcal/day, adjusting based on body condition. Monitor body weight and energy level monthly; if vomiting recurs or appetite wanes, revert to a stricter hepatic formula and schedule a re-check.
Abdominal ultrasonography with Doppler assessment of the liver and gallbladder can reveal parenchymal texture changes, fibrosis, nodules or a gallbladder mucocele that would explain the cholestatic enzymes. A percutaneous or laparoscopic liver biopsy with quantitative copper analysis is the gold standard for diagnosing copper-associated chronic hepatitis and staging fibrosis; it directly addresses the elevated ALT 285 U/L and bile acids 45 µmol/L. Coagulation profile (PT, aPTT) is essential before biopsy because hypoalbuminaemia 2.1 g/dL and hepatic dysfunction can reduce clotting factors. Basal cortisol or ACTH stimulation testing should be considered to evaluate for hyperadrenocorticism as a contributor to the marked ALP 520 U/L. Finally, re-check serum chemistry and bile acids 4–6 weeks after initiating therapy to document response and adjust treatment.
Several parameters stand out as abnormal in your dog’s profile. ALT 285 U/L and AST 87 U/L are liver-cell enzymes; when hepatocytes are injured they leak these proteins into the blood. ALP 520 U/L and GGT 28 U/L belong to the cholestatic group, rising when bile ducts are irritated or blocked. Bile acids 45 µmol/L stay inside the enterohepatic circulation when the liver is healthy; a high value shows they are spilling into the bloodstream, signalling impaired bile flow or poor hepatocyte clearance. Albumin 2.1 g/dL is an important protein made by the liver; low levels warn that the liver’s synthetic machinery is faltering.
An option your veterinarian might discuss is ursodeoxycholic acid, a hydrophilic bile acid that stimulates bile flow and protects cholangiocytes by replacing more toxic bile acids. It works by choleresis and immunomodulation, potentially lowering ALP and GGT. For chronic hepatitis, corticosteroid-sparing immunosuppressives such as cyclosporine (calcineurin inhibitor) may be considered; this drug selectively dampens T-cell mediated inflammation, thereby reducing ALT. In copper-overloaded Labradors, chelation therapy with d-penicillamine binds copper ions, forming a soluble complex excreted in urine, which gradually reduces hepatic copper and ALT.
Hypoalbuminaemia can be supported nutritionally and pharmacologically. Branched-chain amino acid supplementation provides substrates that the diseased liver can still process into albumin. If ascites develops, spironolactone, an aldosterone antagonist diuretic, may be introduced to spare potassium while mobilising fluid. Finally, antioxidant classes such as silymarin (from milk thistle) stabilise hepatocyte membranes and scavenge free radicals, potentially improving both ALT and bile acids. Each of these therapeutic pathways aims at a different facet of liver disease, and your veterinarian will tailor the combination based on diagnostic findings and treatment response.
The following peer-reviewed and institutional resources form the scientific basis for veterinary laboratory medicine and the reference standards used in this report:
Links open external websites. Always consult a licensed veterinarian for all clinical decisions.